Search Results - "Hsia, Elizabeth"

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial by Mease, Philip J, Rahman, Proton, Gottlieb, Alice B, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, McInnes, Iain B

“…The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds…”
Get full text

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial by Deodhar, Atul, Helliwell, Philip S, Boehncke, Wolf-Henning, Kollmeier, Alexa P, Hsia, Elizabeth C, Subramanian, Ramanand A, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Ritchlin, Christopher T

“…Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of…”
Get full text

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study by Kavanaugh, Arthur, Husni, M Elaine, Harrison, Diane D, Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H, Hsia, Elizabeth C

“…To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA). In this phase III, randomized, double-blind,…”
Get full text

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis by McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D., Heijde, Désirée, Mease, Philip J.

“…Objective To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19 subunit (IL‐23p19) inhibitor, in patients with active psoriatic…”
Get full text

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial by Smolen, Josef S, Prof, Kay, Jonathan, MD, Doyle, Mittie K, MD, Landewé, Robert, MD, Matteson, Eric L, Prof, Wollenhaupt, Jürgen, Prof, Gaylis, Norman, MD, Murphy, Frederick T, MD, Neal, Jeffrey S, MD, Zhou, Yiying, PhD, Visvanathan, Sudha, PhD, Hsia, Elizabeth C, MD, Rahman, Mahboob U, MD

“…Summary Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFα inhibitor…”
Get full text

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis by Kay, Jonathan, Fleischmann, Roy, Keystone, Edward, Hsia, Elizabeth C, Hsu, Benjamin, Mack, Michael, Goldstein, Neil, Braun, Jürgen, Kavanaugh, Arthur

“…To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials. Golimumab 50 and…”
Get more information

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study by Deodhar, Atul, Gottlieb, Alice B, Boehncke, Wolf-Henning, Dong, Bin, Wang, Yuhua, Zhuang, Yanli, Barchuk, William, Xu, Xie L, Hsia, Elizabeth C, AELION, Jacob, AMARELO-RAMOS, Juan, BALSA, Alejandro, BERGHEA, Florian, BRZEZICKI, Jan, BURNETTE, Michael, FRETZIN, Scott, GARCÍA-CARAZO, Sara, GLADSTEIN, Geoffrey, GOMEZ-REINO, Juan, GOODERHAM, Melinda, GONZÁLEZ-FERNÁNDEZ, Carlos, GOTTLIEB, Alice, GRATACOS, Jordi, HAALAND, Derek, KAMALOVA, Rima, LESZCZYNSKI, Piotr, MARTIN-MOLA, Emilio, MASLYANSKY, Alexey, NAVARRO, Federico, OPRIS, Daniela, PAPP, Kim, PERLAMUTROV, Yuriy, PHILIPP, Sandra, RACEWICZ, Artur, REBROV, Andrey, RELL-BAKALARSKA, Maria, ROSMARIN, David, RUBBERT-ROTH, Andrea, SHERGY, William, SHIRINSKY, Ivan, SONIN, Dmitry, STANISLAV, Marina, SUKHAREV, Alexey, TEMNIKOV, Vadim, VINOGRADOVA, Irina, WAYTZ, Paul, YAKUSHEVICH, Vladimir

“…Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis…”
Get full text

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study by Deodhar, Atul, Reveille, John D, Harrison, Diane D, Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H, Hsia, Elizabeth C

“…To evaluate the safety and efficacy of intravenous golimumab (GOL) in patients with active ankylosing spondylitis (AS). In a phase III, randomized,…”
Get full text

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial by Baker, Joshua F, Ostergaard, Mikkel, Emery, Paul, Hsia, Elizabeth C, Lu, Jiandong, Baker, Daniel G, Conaghan, Philip G

“…To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA…”
Get more information

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis by Leu, Jocelyn H, Adedokun, Omoniyi J, Gargano, Cynthia, Hsia, Elizabeth C, Xu, Zhenhua, Shankar, Gopi

“…Abstract Objective Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard…”
Get full text

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by Husni, M Elaine, Deodhar, Atul, Schwartzman, Sergio, Chakravarty, Soumya D, Hsia, Elizabeth C, Leu, Jocelyn H, Zhou, Yiying, Lo, Kim H, Kavanaugh, Arthur

“…Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed…”
Get full text

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis by Rahman, Proton, Mease, Philip J, Helliwell, Philip S, Deodhar, Atul, Gossec, Laure, Kavanaugh, Arthur, Kollmeier, Alexa P, Hsia, Elizabeth C, Zhou, Bei, Lin, Xiwu, Shawi, May, Karyekar, Chetan S, Han, Chenglong

“…The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on…”
Get full text

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies by McGonagle, Dennis, McInnes, Iain B, Deodhar, Atul, Schett, Georg, Shawi, May, Kafka, Shelly, Karyekar, Chetan S, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Ritchlin, Christopher T, Rahman, Proton, Mease, Philip J

“…To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibitor approved for PsA, on enthesitis and assess relationships between…”
Get full text

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis by Kay, Jonathan, Fleischmann, Roy, Keystone, Edward, Hsia, Elizabeth C, Hsu, Benjamin, Zhou, Yiying, Goldstein, Neil, Braun, Jürgen

“…Assess 5-year golimumab (GOL) safety in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Subcutaneous (SC) GOL (50 mg or…”
Get full text

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study by Reveille, John D, Deodhar, Atul, Caldron, Paul H, Dudek, Anna, Harrison, Diane D, Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H, Hsia, Elizabeth C

“…Evaluate safety and efficacy of intravenous (IV) golimumab (GOL) in patients with active ankylosing spondylitis (AS) through 1 year. A total of 208 patients…”
Get full text

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis by Husni, M. Elaine, Kavanaugh, Arthur, Murphy, Frederick, Rekalov, Dmytro, Harrison, Diane D., Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H., Hsia, Elizabeth C.

“…Objective The present study was undertaken to evaluate the safety and efficacy of intravenous (IV) golimumab in patients with active psoriatic arthritis (PsA)…”
Get full text

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis by Rahman, Proton, Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Mease, Philip J, Gottlieb, Alice B, Kafka, Shelly, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Shawi, May, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Ramachandran, Paraneedharan, Zhuang, Yanli, McInnes, Iain B

“…Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the…”
Get full text

Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: Risk reduction in a chronic inflammatory disease by Wasko, Mary Chester, Kay, Jonathan, Hsia, Elizabeth C., Rahman, Mahboob U.

“…Objective To perform a systematic literature review of the potential association among molecular markers of inflammation, alterations in body composition, and…”
Get full text

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age by Tesser, John, Kafka, Shelly, DeHoratius, Raphael J, Xu, Stephen, Hsia, Elizabeth C, Turkiewicz, Anthony

“…To evaluate the safety and efficacy of intravenous golimumab + methotrexate (MTX) in patients with active rheumatoid arthritis (RA) aged < 65 years and those ≥…”
Get full text

The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy by Emery, Paul, Fleischmann, Roy, van der Heijde, Désirée, Keystone, Edward C., Genovese, Mark C., Conaghan, Philip G., Hsia, Elizabeth C., Xu, Weichun, Baratelle, Anna, Beutler, Anna, Rahman, Mahboob U.

“…Objective To evaluate the effects of golimumab on radiographic progression in patients with rheumatoid arthritis (RA). Methods Methotrexate (MTX)–naive…”
Get full text